Therapeutic Approaches for Acute Promyelocytic Leukaemia: Moving Towards an Orally Chemotherapy-Free Era

Zheng-Li Xu and Xiao-Jun Huang*

Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

The treatment of acute promyelocytic leukaemia (APL) has evolved dramatically over the past several decades, making the disease a highly curable form of acute leukaemia. The discoveries of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) were landmark events, leading to historic revolutions in the treatment of APL. One major change was from chemotherapy-based to chemotherapy-free treatment regimens, and the combination of ATRA plus ATO without chemotherapy has been recommended as the standard therapy for non-high-risk APL. The other major change was from the intravenous administration of medicine in the hospital to a largely home-based oral approach, which is a more cost-effective and convenient treatment model. In this review, we focus on the evolution of therapeutic approaches for APL, as well as the challenges that remain with the current approaches.

Keywords: acute promyelocytic leukaemia, oral, chemotherapy-free, all-trans retinoic acid, Realgar-Indigo naturalis formula

INTRODUCTION

Acute promyelocytic leukaemia (APL) was associated with a severe bleeding tendency and an extremely poor prognosis in history (1). In the last thirty years, the therapeutic outcomes of APL have markedly improved. The combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is reported to result in complete remission (CR) rates exceeding 90% and overall survival (OS) rates of 85–99% (2–8).

In the evolution of therapeutic approaches for APL, the first historical milestone was chemotherapy based on anthracyclines (9). The use of daunorubicin in induction therapy improved CR rate from 13 to 55% in APL (9). However, the median duration of remission remained poor, ranging from 11 to 29 months (10, 11). Subsequently, the first therapeutic results of ATRA and ATO were published in 1988–1996 (12, 13). Besides, various oral arsenic formulations were also introduced (14). These represent the three landmarks that contributed to two revolutions in the treatment of APL: from chemotherapy-based to chemotherapy-free regimens and from the intravenous administration of medicine in a hospital to a largely home-based oral approach. These evolutions have made the treatment of APL more efficient, convenient and affordable. Here, we
review the significant changes in treatment approaches for APL, as well as the challenges that remain with the current approaches.

THE FIRST REVOLUTION: FROM CHEMOTHERAPY-BASED TO CHEMOTHERAPY-FREE REGIMENS

The adoption of ATRA and ATO as treatments constituted a landmark in the development of targeted therapy for APL. In the 1980s, leukaemic promyelocytes were found to possess the unique capability to undergo differentiation when exposed to ATRA (12). Later, ATO was found to be capable of eradicating APL-initiating cells, resulting in a curative effect (15).

Improved Remission Rates and Survival Outcomes With the Combination of ATRA/ATO

In the pre-ATRA period, anthracycline-based chemotherapy regimen with or without cytosine arabinoside (Ara-C) was applied in newly diagnosed APL patients. With anthracycline alone, complete remissions were in about 50–70% of patients and median duration of remission was 6.5–26 months (9, 16). With anthracycline plus Ara-C regimen, CR rates ranged from 68 to 72% (17, 18). In the chemotherapy alone era, only 35–45% of patients achieved a cure with anthracycline-based consolidation therapy (19).

When ATRA was introduced as an APL differentiation therapy, the treatment paradigm evolved to ATRA-based regimens (combined ATRA and chemotherapy). The ATRA-based regimens in the induction phase produced improved CR rates over 90% (20–22). After obtaining CR, consolidation therapy composed of chemotherapy with or without ATRA was administered, and the long-term disease-free survival (DFS) with this treatment paradigm was estimated to range from 68.5 to 85.6% (20–23).

The introduction of the ATRA/ATO combination as a synergistic therapy created new possibilities for the treatment of APL. In the initial attempt, combined ATRA/ATO for the induction of remission followed by consolidation chemotherapy resulted in a CR rate of 95.2% and a DFS rate of 100% with a median follow-up of 18 months (24). In subsequent studies, the combination of ATRA and ATO was applied as both induction and consolidation therapy, which resulted in CR rates of 89%-92% and an OS rate of 85% (2, 3).

Optimal Place of Combined ATRA/ATO in Newly Diagnosed APL

The APML4 study combined ATRA with idarubicin in induction therapy and used ATRA-ATO as consolidation therapy in 124 patients with all-risk groups. The survival outcomes were inspiring, with 5-year OS of 94% and EFS of 90% (7). The AML17 trial included all risk groups for newly diagnosed APL and compared a chemotherapy-free ATRA-ATO treatment regimen with the standard chemotherapy-based regimen (ATRA and idarubicin). Burnett et al. showed that the CR rates were comparable between the two groups, but ATRA-ATO group was associated with a better 4-year EFS (91.0 vs. 70.0%, P = 0.002) (6).

In newly diagnosed non-high-risk APL patients, a randomized multi-centre trial conducted by Lo-Coco et al. in 2013 compared ATRA-ATO combination therapy with ATRAidarubicin therapy for induction and consolidation therapy in newly diagnosed patients and showed similar CR rates (100 vs. 95%) but improved 2-year EFS in the former (97 vs. 86%) (5). In 2017, after a prolonged follow-up among the extended therapy patients, the EFS at 50 months for patients in the ATRA-ATO versus ATRA-chemotherapy arms were 97.3 vs. 80.0% (25). Based on the above results, the combined use of ATO and ATRA as a first-line treatment for non-high-risk APL has been adopted by the National Comprehensive Cancer Network (NCCN) guidelines (26) and the European Leukaemia Net (ELN) recommendations (27).

A chemotherapy-free protocol has also been studied in newly diagnosed high-risk APL patients. Researchers from the University of Texas MD Anderson Cancer Center reported a CR rate of 96% and a 5-year EFS of 81% in high-risk patients treated with ATO, ATRA plus gemtuzumab ozogamycin [GO] for induction and ATRA/ATO for consolidation therapy (8). More recently, the SWOG Cancer Research Network has applied the chemotherapy-free combination of ATRA, ATO and GO for induction therapy followed by chemotherapy included for consolidation treatment in high-risk patients. Overall, 86% of the patients achieved CR, and the 3-year EFS was 78%, with the largest sample size (N = 70) of high-risk patients (28). Currently, there is no definitely recommended treatment option for high-risk patients (26, 27).

Reduced Chemotherapy-Related Toxicity in the ATRA/ATO Period

The synergistic activity of combined ATRA and ATO has been indicated in the treatment of APL, thereby lessening the need for chemotherapy and reducing the risk of chemotherapy-related toxicities. Specifically, such a chemotherapy-free regimen is likely to reduce the risk of myelosuppression-related complications, cardiototoxicity associated with anthracycline exposure, and secondary malignancies associated with the use of ATRA plus traditional chemotherapy (29). In a previous study, 17% cases treated with ATRA plus idarubicin developed secondary malignancies (30).

Although ATRA plus ATO was associated with more frequent increases in liver enzymes and QTc prolongation, these effects were reversible and manageable with reduced doses or the temporary discontinuation of the drug (5). We should note that chronic arsenic exposure has potential risk of causing cancer, but there is no clinical evidence.

THE SECOND REVOLUTION: FROM INTRAVENOUS ADMINISTRATION TO AN ORAL APPROACH

Intravenous ATO is inconvenient, involves frequent hospitalization and requires the maintenance of vascular access. Thus, an oral arsenic drug has been anticipated for a long time; this oral approach could facilitate a largely home-based protocol and further promote the quality of life of APL patients.
In China, the study of oral arsenic formulations has a long history. There are three main inorganic arsenic forms, namely, red arsenic (tetrarsenic tetra-sulfide, As₄S₄, which is isolated from realgar), yellow arsenic (As₂S₃, also known as orpiment), and white arsenic (arsenic trioxide, As₂O₃, which is made by burning realgar or orpiment) (31). Beginning in the 1970s, arsenic oxide (As₂O₃) was used to treat APL (1). In the decades that followed, different oral arsenic formulations have been tried, and excellent outcomes in APL have been reported (32, 33).

Realgar-Indigo naturalis formula (RIF) is a drug compound containing 30 mg of realgar, 125 mg of Indigo naturalis, 50 mg of Radix salviae miltiorrhizae, 45 mg of Radix pseudostellariae, and 20 mg of garment film in one pill. Based on its clinical results (34) and the anti-APL activity in vitro and in vivo (35), RIF has been approved by the Chinese FDA and has been commercialized and commonly available in China since 2009.

**Comparable Efficacy Between RIF and Intravenous Arsenic Formulations in Newly Diagnosed APL**

**Chemotherapy Included Protocol in Consolidation Period**

Huang’s group led a multi-centre, randomized controlled phase III study (APL07) comparing oral RIF (60 mg/kg) and ATO (0.16 mg/kg) in newly diagnosed APL patients as both induction and maintenance therapies from November 2007 through September 2011 (36). All patients received three courses of consolidation chemotherapy and maintenance treatment with sequential ATRA followed by either RIF or ATO for two years. With a median follow-up of 39 months, the 2-year DFS was 98.1% in the RIF group and 95.5% in the ATO group. No significant difference was noted between the RIF and ATO groups with regard to the CR rate (99.1 vs. 97.2%; \( P = 0.62 \)). In 2016, Huang’s group updated the follow-up data and reported that the estimated 7-year EFS rates were similar between the RIF and ATO groups (93.7 vs. 89.4%; \( P = 0.37 \)). In addition, the estimated 7-year incidences of relapse and EFS were also similar between the high-risk and non-high-risk groups (2.4 vs. 5.0%; \( P = 0.55 \); 91.2% vs. 91.5%, \( P = 0.74 \)) (37).

In the treatment of paediatric APL, another randomized, multi-centre non-inferiority trial was conducted in China to determine whether intravenous ATO can be replaced by oral RIF (38). A total of 82 patients who were 16 years old or younger were randomly assigned to the ATO (n = 42) or RIF (n = 40) group. In this trial, patients received three courses of consolidation therapy containing ATRA, ATO and low-intensity chemotherapy with mitoxantrone; cytarabine was added for high-risk patients. The estimated 5-year EFS was 100% in both groups after a median 3-year follow-up.

**RIF and ATRA Without Chemotherapy**

Huang et al. conducted a single-centre pilot study to evaluate the efficacy of oral arsenic and ATRA without chemotherapy in newly diagnosed non-high-risk APL patients. A total of 20 consecutive patients were given oral arsenic RIF (60 mg/kg) and ATRA (25 mg/m²) as induction therapy and then RIF on a schedule of 4 weeks on and 4 weeks off and ATRA on a schedule of 2 weeks on and 2 weeks off for 7 months as post-remission therapy (39). All patients achieved haematologic complete remission after a median time of 29.5 days. The rate of complete molecular remission was 65% at 3 months and 100% at 6 months (39). This preliminary result is encouraging and provides initial evidence for the success of a largely home-based treatment protocol for the treatment of non-high-risk APL.

Subsequently, these findings were confirmed by a multi-centre, non-inferiority, open-label, randomized, controlled phase 3 trial at 14 centres in China (40). In this trial, RIF (60 mg/kg/d) or arsenic trioxide (0.15 mg/kg/d) and ATRA (25 mg/m²/d) were administered until CR was achieved. The consolidation therapy was RIF (60 mg/kg/d) or intravenous arsenic trioxide (0.15 mg/kg/d) in one 4 weeks on and 4 weeks off regimen for four cycles and ATRA (25 mg/m²/d) in one 2 weeks on and 2 weeks off regimen for seven cycles. The estimated 2-year EFS and OS were 97% vs. 94% (\( P = 0.49 \)) and 100% vs. 94% (\( P = 0.049 \)), respectively. This study has suggested that non-high-risk APL can be cured using oral arsenic plus ATRA without conventional chemotherapy.

Huang’s group has tried to extend the outpatient model to newly diagnosed high-risk APL patients (41). A total of 20 patients were included in a single-centre cohort study. All subjects received oral arsenic RIF (60 mg/kg/d) and ATRA (25 mg/m²/d) as induction therapy until CR was achieved. Hydroxyurea (Hu, 3 g/d) or Hu (3 g/d) plus cytarabine (200 mg/d) was used to reduce the leukaemia burden if patients’ WBC counts were (10–20) × 10⁹/L or over 20 × 10⁹/L before induction until the WBC count was lower than 10 × 10⁹/L. The consolidation therapy was consistent with that in non-high-risk cases (39), including RIF in a 4 weeks on and 4 weeks off regimen for four cycles and ATRA in a 2 weeks on and 2 weeks off regimen for seven cycles. With a median follow-up of 33 months, 20 patients (100%) achieved a CR after a median time of 30 days. The 3-year estimated OS and EFS were 100% and 89.4%, respectively.

**Evidence of Oral As₂O₃ Solution in Relapsed or Newly Diagnosed APL**

More recently, the use of oral As₂O₃ solution in reinduction/maintenance regimens in relapsed APL, as a front-line treatment in newly diagnosed APL and in maintenance regimens after first CR have been reported by Gill’s team with encouraging outcomes (42–44).

Since 2002, Gill et al. have conducted a prospective study among APL patients who have experienced their first relapse and used protocols that involve oral As₂O₃ reinduction followed by As₂O₃ maintenance. In detail, the reinduction therapy comprised oral As₂O₃, ATRA and ascorbic acid (AAA) on days 1–28 and idarubicin for 5 days. After achieving CR2, patients received consolidation therapy with idarubicin. After the completion of consolidation, maintenance therapy with the AAA regimen (2 weeks every 2 months for 2 years per protocol) was administered. Finally, all 73 patients obtained CR2 after oral As₂O₃-based reinduction and received oral As₂O₃ based maintenance. The 5-year and 10-year OS rates in the cohort were 79.5 and 67.3%, respectively (42). This cohort study showed that oral As₂O₃-based reinduction remained effective despite previous exposures, and it was an effective maintenance therapy for patients in CR2.
Subsequently, Gill’s team brought oral As₂O₃ incorporation into front-line treatment in newly diagnosed APL patients. Sixty-two consecutive patients received the AAA regimen with additional daunorubicin in younger patients for induction therapy. In the comparator group, 37 subjects received similar consolidation and maintenance therapies but did not receive oral As₂O₃ for induction therapy. The CR rates were both 100%, and the 5-year OS rates were comparable (100 vs. 96.9%, \( P = 0.21 \)) in the arsenic and non-arsenic induction subgroups. However, the 5-year DFS in the arsenic induction subgroup was significantly superior to that of the non-arsenic induction subgroup (100 vs. 90.5%, \( P = 0.03 \)) (43).

Recently, the role of As₂O₃ in the maintenance of CR1 in APL has also been demonstrated. A total of 129 consecutive adult patients achieved CR1 with conventional induction and consolidation. Then, they underwent AAA maintenance for 2 years. At a median follow-up of 100 months, the 10-year DFS and OS were estimated to be 85 and 87%, respectively. This analysis indicated that AAA maintenance therapy is an effective choice for long-term survival in all risk categories of APL (44).

**Reduced Cost, Shorter Hospitalization, and Improved Quality of Life With Oral Forms**

Jiang et al. conducted a retrospective study and compared the medical costs and length of hospital stay between oral RIF plus ATRA and intravenous ATO plus ATRA as the first-line treatment in APL patients involved in the clinical trial APL07 at Peking University People’s Hospital. The median total medical costs were significantly lower in the RIF group ($131,834.49) than in the ATO group ($241,366.98) (\( P < 0.0001 \)). The median total length of hospital stay in the RIF group was also obviously shorter (48 days) than that in the ATO group (54 days) (\( P < 0.0001 \)) (45). This was also consistent with the results in the paediatric cohort, with results of 67.8 vs. 43.9 days and 68.1 vs. 48.1 days for non-high-risk and high-risk patients in the ATO and RIF groups, respectively.

Oral arsenic formulations can be administered outside the hospital, which reduces the need for hospital visits, resulting in a superior quality of life than that associated with intravenous ATO (46). In our single-centre pilot study, patients received RIF plus ATRA as induction and post-remission treatment. They resumed their usual lifestyle during post-remission therapy and rated their quality of life as nearly normal on the FACT-G questionnaire (39). In the respective cohorts from Beijing, most patients in the RIF group could resume their work or study status with a relatively better quality of life during maintenance therapy after consolidation chemotherapy (45).

**CHALLENGES AND UNRESOLVED ISSUES**

First, there is concern that the combination of two differentiating drugs without chemotherapy might lead to an increased risk of leucocytosis and differentiation syndrome. It has been reported that 35%-47% of non-high-risk adults develop leucocytosis after chemotherapy-free induction therapy, while 24% develop leucocytosis after ATRA plus chemotherapy induction (5, 25, 39, 47). In paediatric APL patients, the incidence of leucocytosis is reported to be much higher, reaching more than 90% (48).

In addition, different kinetics of WBC proliferation were observed during induction with oral arsenic plus ATRA and ATO plus ATRA. A higher WBC count was observed in the RIF group than in the ATO group after 10 days of treatment (9.22×10⁹/L vs. 4.10×10⁹/L, \( P = 0.015 \)) (49). Currently, prompt supportive measures such as cyto reduction chemotherapy and prophylactic corticosteroids have been proven to be useful to minimize the impact of leucocytosis (47).

In addition, CNS relapse is uncommon in patients with APL treated with traditional ATRA plus chemotherapy regimens. However, there are no formal data reporting its incidence and suggesting the need for CNS prophylaxis in the chemotherapy-free era (27, 50). It is necessary to prolong the follow-up time to determine the incidence and to conduct a randomized study to identify the optimal prophylactic strategy.

Challenges remain regarding the therapeutic use of chemotherapy-free regimens for high-risk APL. As mentioned in the updated ELN guidelines, two potential options for high-risk patients are ATRA plus ATO with the addition of appropriate cyto reduction chemotherapy and conventional ATO plus chemotherapy. The use of chemotherapy-free or minimal chemotherapy needs to be explored in more randomized trials to enable a comparison with conventional treatment in patients in separate high-risk categories.

In summary, APL used to have a high mortality rate; however, the majority of patients can be cured at present. The emergence of ATRA and arsenic represents the beginning of targeted therapy for APL, and the advent of oral arsenic formulations allows a largely home-based oral protocol. Both therapeutic revolutions have made the treatment of APL more efficient, convenient, and affordable. In the future, challenges regarding the appropriate sequence of chemotherapy-free regimens in high-risk patients and the long-term efficacy in the new era need to be addressed.

**AUTHOR CONTRIBUTIONS**

X-JH designed the review. Z-LX and X-JH wrote the manuscript and gave final approval for the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was partly supported by the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81621001), The Key Program of National Natural Science Foundation of China (Grant No. 81530046), The National Key Research and Development Program of China (No. 2017YFA0104500) and Peking University Clinical Scientist Program (No. BMU2019LCKXJ003).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.586004/full#supplementary-material
REFERENCES

1. Wang ZH, Chen Z. Acute promyelocytic leukaemia: from highly fatal to highly curable. Blood (2008) 111(5):2055–15. doi: 10.1182/blood-2007-07-102798
2. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukaemia. Blood (2006) 107(9):3469–73. doi: 10.1182/blood-2005-10-40006
3. Ravandi F, Estey E, Jones D, Faderl S, O’Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukaemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol (2009) 27(4):504–10. doi: 10.1200/JCO.2008.18.6130
4. Iland HJ, Bradstock K, Supple SG, Catalano A, Collins M, Hertzberg M, et al. Acute promyelocytic leukemia: a study of 39 cases with identical PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood (2007) 110(1):59–66. doi: 10.1182/blood-2006-08-043992
5. Xu and Huang Orally Chemo-Free Era in APL
6. Zeidan AM, Gore SD. New strategies in acute promyelocytic leukemia: a randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukaemia who have become negative for PML-RARA beta transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood (2007) 110(1):59–66. doi: 10.1182/blood-2006-08-043992
7. Xie J, Qin YT, Shao Y, Wang J, Huang SL, Shi ZZ, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukaemia. Proc Natl Acad Sci U S A (2004) 101(15):5328–35. doi: 10.1073/pnas.040053101
8. Platzbecker U, Avvisati G, Ciccioni I, Thiede C, Paoloni F, et al. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. J Clin Oncol (2017) 35(6):605–12. doi: 10.1200/JCO.2016.67.1982
9. Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bishby D, et al. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2019) 17(6):721–49. doi: 10.6004/jnccn.2019.0028
10. Sanz MA, Fenaux P, Tallman MS, Estey EH, Lowenberg B, Naoe T, et al. Management of acute promyelocytic leukaemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood (2019) 133(15):1630–43. doi: 10.1182/blood-2019-01-984980
11. Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, et al. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv (2020) 4(8):1683–90. doi: 10.1182/bloodadvances.2019001278
12. Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukaemia. Ann Hemtol (2002) 81(9):504–7. doi: 10.1007/s00277-002-0534-8
13. Lightara A, Rodriguez I, Kantarjian H, O’Brien S, D’Aversa N, Garcia-Manero, et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia. Blood (2008) 112(4):982–97. doi: 10.1182/blood-2007-03-092431
14. Eghtedar A, Rodriguez I, Kantarjian H, O’Brien S, D’Aversa N, Garcia-Manero, et al. Incidence of secondary neoplasms in patients with acute promyelocytic leukemia. Blood (2008) 112(4):982–97. doi: 10.1182/blood-2007-03-092431
15. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer (2002) 2(9):705–13. doi: 10.1038/nrc887
16. Lu DP, Yue JY, Jiang B, Wang Q, Lin Y, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukaemia: a pilot report. Blood (2002) 99(9):3136–43. doi: 10.1182/blood.V99.9.3136
17. Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW, et al. Systemic availability of arsenic from oral arsenic-tetraoxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol (2002) 58(8):521–6. doi: 10.1007/s00228-002-0514-x
18. Huang SL, Guo AX, Xiang Y. Clinical study of the compound Qingdai tablets for the treatment of acute promyelocytic leukaemia. Chin J Hematol (1995) 16(1):26–8.
35. Wang L, Zhou GB, Liu P, Song JH, Liang Y, Yan XJ, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturals as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U States America (2008) 105(12):4826–31. doi: 10.1073/pnas.0712365105

36. Zhu HH, Wu DP, Jia JS, Wang JX, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. J Clin Oncol Off J Am Soc Clin Oncol (2013) 31(33):4215–21. doi: 10.1200/JCO.2013.48.8312

37. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, et al. Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid. Br J Haematol (2016) 174(5):820–2. doi: 10.1111/bjh.13809

38. Yang MM, Wan WQ, Luo JS, Zheng MC, Huang K, Yang LH, et al. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturals formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. Am J Hematol (2018) 93(12):1467–73. doi: 10.1002/ajh.25271

39. Zhu HH, Huang XJ. Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. New Engl J Med (2014) 371(23):2239–41. doi: 10.1056/NEJMc1412035

40. Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol (2018) 19(7):871–9. doi: 10.1016/S1470-2045(18)30295-X

41. Zhu HH, Liu YR, Jia JS, Qin YZ, Zhao XS, Lai YY. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood (2018) 131(26):2987–9. doi: 10.1182/blood-2018-02-834051

42. Gill H, Yim R, Lee HKK, Mak V, Lin SY, Kho B, et al. Long-term outcome of relapsed acute promyelocytic leukaemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study. Cancer (2018) 124(11):2316–26. doi: 10.1002/cncr.31327

43. Gill H, Kumara CR, Yim R, Hwang YI, Chan TSY, Yip SF, et al. Oral arsenic trioxide incorporation into frontline treatment with all-trans retinoic acid and chemotherapy in newly diagnosed acute promyelocytic leukaemia: A 5-year prospective study. Cancer (2019) 125(17):3001–12. doi: 10.1002/cncr.32180

44. Gill HS, Yim R, Kumara CR, Tse E, Kwong YL. Oral arsenic trioxide, all-trans retinoic acid, and ascorbic acid maintenance after first complete remission in acute promyelocytic leukaemia: Long-term results and unique prognostic indicators. Cancer (2020) 126(14):3244–54. doi: 10.1002/cncr.32937

45. Jiang H, Liang GW, Huang XJ, Jiang Q, Han S, Shi LW, et al. Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukaemia. Leuk Res (2015) 39(12):1319–24. doi: 10.1016/j.leukres.2015.09.007

46. Ravandi F, Stone R. Acute Promyelocytic Leukemia: A Perspective. Clin Lymphoma Myeloma Leuk (2017) 17(9):543–4. doi: 10.1016/j.clml.2017.06.037

47. Abedin S, Altman JK. Acute promyelocytic leukemia: preventing early complications and late toxicities. Hematol Am Soc Hematol Educ Program (2016) 2016(1):10–5. doi: 10.1182/asheducation-2016.1.10.

48. Zhang J, Zou Y, Chen Y, Guo Y, Yang W, Chen X, et al. Role of cytarabine in paediatric acute promyelocytic leukaemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial. BMC Cancer (2018) 18(1):374. doi: 10.1186/s12885-018-4280-2

49. Wang F, Jia JS, Wang J, Zhao T, Jiang Q, Jiang H, et al. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukaemia. Leuk Res (2017) 61:68–4. doi: 10.1016/j.leukres.2017.09.006

50. Ravandi F. Treatment of Acute Promyelocytic Leukemia With No or Minimal Chemotherapy: Now a Reality in Common Clinical Practice. J Oncol Pract (2018) 14(11):663–4. doi: 10.1200/JOP.18.00537

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Xu and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.